In response to the current worldwide pandemic, CytoDyn (CYDY) is frenetically tracking down an FDA approval for its monoclonal antibody, leronlimab in treatment of COVID-19. I was initially quite skeptical of this quest, but I have slowly warmed to the prospect.
As matters now stand, I am waiting and watching with guarded optimism as it goes through the early stages of revealing data from its COVID-19 clinical trials. This article discusses the current status of CytoDyn's COVID-19 quest and explains my bullish outlook for CytoDyn, albeit an outlook that recognizes daunting challenges.